340 related articles for article (PubMed ID: 36549781)
21. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
[TBL] [Abstract][Full Text] [Related]
23. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
24. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
[TBL] [Abstract][Full Text] [Related]
29. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
31. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
33. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev NS; Ainsworth G; Brown S; Pickering L; Waddell T; Fife K; Griffiths R; Sharma A; Katona E; Howard H; Velikova G; Maraveyas A; Brown J; Pezaro C; Tuthill M; Boleti E; Bahl A; Szabados B; Banks RE; Brown J; Venugopal B; Patel P; Jain A; Symeonides SN; Nathan P; Collinson FJ; Powles T
J Clin Oncol; 2024 Jan; 42(3):312-323. PubMed ID: 37931206
[TBL] [Abstract][Full Text] [Related]
34. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
[TBL] [Abstract][Full Text] [Related]
35. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
36. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K
Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
39. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
